Research and Development

Bristol-Myers Squibb and partner AstraZeneca have been granted FDA approval for a new drug to treat rare and potentially fatal …

Rupert Gowrley is leaving his role as joint head at MHP Health in order to start with Bupa as its …

Eli Lilly’s once-weekly diabetes candidate dulaglutide has matched Novo Nordisk’s established once-daily Victoza (liraglutide) when it comes to lowering blood …

Biopharma firm UCB has confirmed its current chief executive Roch Doliveux is to be replaced by Jean-Christophe Tellier. Tellier (pictured) …

The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …

A little more than a year ago, Lisa Hinsley’s prospects were not good. The mother of three had been diagnosed …

Healthcare data services firm Exco InTouch has appointed Laurence Burke as its vice president of Operations. Burke takes over 20 …

A key adviser to the European regulator has said that Gilead Sciences’ fixed-dose combination of Sovaldi and ledipasvir can be …

Simon Sturge is joining Merck KGaA from Boehringer Ingelheim in order to head its Biosimilars unit. In his new role …

Drug development firm Avillion has appointed Dr Allison Jeynes-Ellis to be its chief executive. By stepping into the role Jeynes-Ellis …

Novartis is celebrating after its investigational pill targeting the most common form of skin cancer met its primary endpoint in …

Life sciences executive search and interim management firm RSA has appointed Claes Zackrisson as its first director of information. Zackrisson …

French firms Servier and small biopharma cancer specialist Cellectis have signed a deal to develop and commercialise one drug targeting …

Regulators have shown the green light to BioMarin Pharmaceutical’s Vimizim as a treatment for a rare enzyme deficiency which affects …